Tempus AI, Inc. remains a Hold due to valuation & lack of profitability; shows strong revenue growth & diversification. Learn more on TEM stock here.
Tempus AI has surged ~75% since August, but current valuations (~15x EV/forward revenue) are unsustainable for its hybrid ...
The company will provide CRO and testing services for the ADAPT program to guide the project's clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback